Nasdaq
$1.02▼ 3.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.7MShares out 1.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.5After-hours26.10.06 05:386-KKey event#●●●#●●●
PURPLE BIOTECH LTD.
Purple Biotech has appointed director Isaac Israel as Interim Chief Executive Officer, effective October 5, 2026. Concurrently, Gil Efron will step down as CEO and transition to the role of Executive Director and Head of Corporate Development while remaining on the Board.…more
$1.02-3.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9After-hours26.09.10 05:016-KKey event
PURPLE BIOTECH LTD.
Purple Biotech Ltd. announced that all proposals presented at the Annual General Meeting of Shareholders held on September 8, 2026, were approved by the shareholders. The meeting results were finalized in accordance with the Israeli Companies Law and the company's articles of association.…more
$1.02-3.88%vs prev closeView filingShare - 9.2Pre-market26.09.02 20:336-KKey event
PURPLE BIOTECH LTD.
On September 2, 2026, Purple Biotech received a Notice of Allowance from the USPTO for its patent application covering tri-specific antibody constructs and methods of use. This patent strengthens the intellectual property protection for the company's proprietary CAPTN-3 platform, supporting the accelerated development of new therapeutic candidates across multiple cancer indications.…more
$1.02-3.88%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.2Pre-market26.09.02 22:24#●●●#●●●
Purple Biotech Shares Surge on U.S. Patent Approval
Purple Biotech shares rose after receiving a Notice of Allowance from the U.S. Patent and Trademark Office for its tri-specific antibody platform. This patent strengthens the company's intellectual property and is expected to accelerate the development of its cancer therapeutic candidates.…more
$1.02-3.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.2Pre-market26.09.02 20:32
●●●●●●●● ●●●●● ●●●●●●
Purple Biotech has been granted a U.S. patent for its tri-specific antibody constructs and methods of use. This development strengthens the intellectual property portfolio supporting the company's proprietary CAPTN-3 immunotherapy platform.…more
$1.02-3.88%vs prev closeShareBenzinga - 9.2Pre-market26.09.02 20:30
●●●●●●●● ●●●●● ●●●●●●
Purple Biotech has received a notice of allowance from the USPTO for its CAPTN-3 modular platform for multispecific antibodies. This patent strengthens the company's intellectual property and supports the flexible development of future oncology therapeutic candidates.…more
$1.02-3.88%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report